ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,334.20
0.00%
Brent Oil
81.965
0.00%
Bitcoin
69,250.01
1.05%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kineta Inc (KA) Share Price

KA Kineta Inc

0.4745
0.0065 (1.39%)
25 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Kineta Inc NASDAQ:KA NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.0065 1.39 0.4745 0.44 0.475 0.4895 0.442001 0.47 21,471 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 5.44M -14.1M -1.3565 -1.39 19.64M
 Type  Size  Price  Time  Units 
 20 4,300 0.4745 22:46:45 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore KA News
15/05/202421:03EDGAR2Form 8-K - Current report
15/05/202421:01GLOBEKineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
08/04/202421:01GLOBEKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
21/03/202420:02GLOBEKineta Reports Full Year 2023 Financial Results and Provides Corporate Update
12/03/202412:00GLOBEKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
29/02/202413:30GLOBEKineta Announces Restructuring and Exploration of Strategic Alternatives
29/02/202412:00EDGAR2Form 8-K - Current report
Period
Draw mode
Data Downloads for KA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Kineta Inc Articles